GlaxoSmithKline is appealing a Delaware federal district judge’s ruling that wiped out a $235 million verdict against Teva Pharmaceuticals for allegedly infringing a patent for the hypertension drug Coreg.
GSK’s Fish & Richardson attorneys on Monday filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit seeking to overturn U.S. District Chief Judge Leonard P. Stark of the District of Delaware’s final judgment last month that Teva’s ”skinny label” for a generic version of Coreg did not induce infringement of GSK’s patent.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]